Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Antoniou

Showing results (311-320 of 395) with videos related to

Pageof 40
Sort By:
Human Molecular Genetics|September 6, 2011
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriersDavid G Cox, Jacques Simard, Daniel Sinnett, et al.
Nature Communications|May 24, 2025
Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classificationMaria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2011
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testingPaul D P Pharoah, Rachel T Palmieri, Susan J Ramus, et al.
Human Genetics|May 21, 2011
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriersKate M Im, Tomas Kirchhoff, Xianshu Wang, et al.
Breast (Edinburgh, Scotland)|November 12, 2025
Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancerAmandine Billaud, Gisella Figlioli, Clémence Mooser, et al.
Human Mutation|February 21, 2018
The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicityMara Colombo, Irene Lòpez-Perolio, Huong D Meeks, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 11, 2021
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variantInge M M Lakeman, Alexandra J van den Broek, Juliën A M Vos, et al.
JAMA Oncology|July 3, 2020
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Valentina Silvestri, Goska Leslie, Daniel R Barnes, et al.
Journal of Medical Genetics|July 14, 2023
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in IsraelHagai Levi, Shai Carmi, Saharon Rosset, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 FamiliesXin Yang, Goska Leslie, Alicja Doroszuk, et al.
Pageof 40

Showing results (311-320 of 395) with videos related to

Sort By:
Pageof 40
Human Molecular Genetics|September 6, 2011
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriersDavid G Cox, Jacques Simard, Daniel Sinnett, et al.
Nature Communications|May 24, 2025
Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classificationMaria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2011
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testingPaul D P Pharoah, Rachel T Palmieri, Susan J Ramus, et al.
Human Genetics|May 21, 2011
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriersKate M Im, Tomas Kirchhoff, Xianshu Wang, et al.
Breast (Edinburgh, Scotland)|November 12, 2025
Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancerAmandine Billaud, Gisella Figlioli, Clémence Mooser, et al.
Human Mutation|February 21, 2018
The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicityMara Colombo, Irene Lòpez-Perolio, Huong D Meeks, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 11, 2021
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variantInge M M Lakeman, Alexandra J van den Broek, Juliën A M Vos, et al.
JAMA Oncology|July 3, 2020
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Valentina Silvestri, Goska Leslie, Daniel R Barnes, et al.
Journal of Medical Genetics|July 14, 2023
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in IsraelHagai Levi, Shai Carmi, Saharon Rosset, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 FamiliesXin Yang, Goska Leslie, Alicja Doroszuk, et al.
Pageof 40